CA2899712C - Methods and compositions for detecting mutations in the human pi3kca (pik3ca) gene - Google Patents
Methods and compositions for detecting mutations in the human pi3kca (pik3ca) gene Download PDFInfo
- Publication number
- CA2899712C CA2899712C CA2899712A CA2899712A CA2899712C CA 2899712 C CA2899712 C CA 2899712C CA 2899712 A CA2899712 A CA 2899712A CA 2899712 A CA2899712 A CA 2899712A CA 2899712 C CA2899712 C CA 2899712C
- Authority
- CA
- Canada
- Prior art keywords
- seq
- nucleotide
- sequence
- oligonucleotide
- detecting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000035772 mutation Effects 0.000 title claims abstract description 84
- 238000000034 method Methods 0.000 title claims abstract description 21
- 108090000623 proteins and genes Proteins 0.000 title abstract description 20
- 239000000203 mixture Substances 0.000 title description 6
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 24
- 201000011510 cancer Diseases 0.000 claims abstract description 17
- 108091034117 Oligonucleotide Proteins 0.000 claims description 93
- 125000003729 nucleotide group Chemical group 0.000 claims description 81
- 239000002773 nucleotide Substances 0.000 claims description 72
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 53
- 239000000523 sample Substances 0.000 claims description 38
- 230000003321 amplification Effects 0.000 claims description 21
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 21
- 108700028369 Alleles Proteins 0.000 claims description 19
- 239000011541 reaction mixture Substances 0.000 claims description 18
- 238000001514 detection method Methods 0.000 claims description 12
- 101100190564 Homo sapiens PIK3CA gene Proteins 0.000 claims description 8
- 108020004705 Codon Proteins 0.000 claims description 3
- 108700026093 human PI3KCA Proteins 0.000 abstract description 16
- 239000003153 chemical reaction reagent Substances 0.000 abstract description 7
- 102000053900 human PI3KCA Human genes 0.000 abstract description 2
- 150000007523 nucleic acids Chemical class 0.000 description 23
- 102000039446 nucleic acids Human genes 0.000 description 21
- 108020004707 nucleic acids Proteins 0.000 description 21
- 102200085789 rs121913279 Human genes 0.000 description 15
- 102200085639 rs104886003 Human genes 0.000 description 14
- 102200085641 rs121913273 Human genes 0.000 description 14
- 102200085635 rs121913274 Human genes 0.000 description 14
- 102200085637 rs121913274 Human genes 0.000 description 14
- 102200085788 rs121913279 Human genes 0.000 description 14
- 102200085790 rs121913281 Human genes 0.000 description 14
- 102200085791 rs121913286 Human genes 0.000 description 14
- 102200085792 rs121913286 Human genes 0.000 description 14
- 238000006243 chemical reaction Methods 0.000 description 13
- 102220197894 rs121913277 Human genes 0.000 description 13
- 102220197790 rs397517201 Human genes 0.000 description 13
- 102220006545 c.1035C>A Human genes 0.000 description 11
- 230000000295 complement effect Effects 0.000 description 9
- 238000011282 treatment Methods 0.000 description 9
- 230000004048 modification Effects 0.000 description 8
- 238000012986 modification Methods 0.000 description 8
- 108091007960 PI3Ks Proteins 0.000 description 7
- 230000037361 pathway Effects 0.000 description 7
- 102000040430 polynucleotide Human genes 0.000 description 7
- 108091033319 polynucleotide Proteins 0.000 description 7
- 239000002157 polynucleotide Substances 0.000 description 7
- 238000003556 assay Methods 0.000 description 6
- 102200085787 rs121913283 Human genes 0.000 description 6
- 101150063858 Pik3ca gene Proteins 0.000 description 5
- 238000007844 allele-specific PCR Methods 0.000 description 5
- 238000009396 hybridization Methods 0.000 description 5
- 206010069754 Acquired gene mutation Diseases 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000037439 somatic mutation Effects 0.000 description 4
- 230000008685 targeting Effects 0.000 description 4
- 102000038030 PI3Ks Human genes 0.000 description 3
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 3
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 3
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 3
- 239000002777 nucleoside Substances 0.000 description 3
- -1 nucleoside triphosphates Chemical class 0.000 description 3
- 238000011275 oncology therapy Methods 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 102220197892 rs121913284 Human genes 0.000 description 3
- 239000001226 triphosphate Substances 0.000 description 3
- 235000011178 triphosphate Nutrition 0.000 description 3
- 241001212017 Brana Species 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
- 108700024394 Exon Proteins 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 125000003275 alpha amino acid group Chemical class 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 2
- 239000002935 phosphatidylinositol 3 kinase inhibitor Substances 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 102100029812 Protein S100-A12 Human genes 0.000 description 1
- 101710110949 Protein S100-A12 Proteins 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 1
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 1
- 102000006943 Uracil-DNA Glycosidase Human genes 0.000 description 1
- 108010072685 Uracil-DNA Glycosidase Proteins 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 125000006487 butyl benzyl group Chemical group 0.000 description 1
- 239000003560 cancer drug Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000006552 constitutive activation Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 229940121647 egfr inhibitor Drugs 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000001506 fluorescence spectroscopy Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000004880 lymph fluid Anatomy 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- 210000001138 tear Anatomy 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000005382 thermal cycling Methods 0.000 description 1
- 229960000575 trastuzumab Drugs 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361780017P | 2013-03-13 | 2013-03-13 | |
| US61/780,017 | 2013-03-13 | ||
| PCT/EP2014/054766 WO2014140061A2 (en) | 2013-03-13 | 2014-03-12 | Methods and compositions for detecting mutations in the human pi3kca (pik3ca) gene |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2899712A1 CA2899712A1 (en) | 2014-09-18 |
| CA2899712C true CA2899712C (en) | 2021-01-05 |
Family
ID=50277211
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2899712A Active CA2899712C (en) | 2013-03-13 | 2014-03-12 | Methods and compositions for detecting mutations in the human pi3kca (pik3ca) gene |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20140272961A1 (enExample) |
| EP (1) | EP2971075B1 (enExample) |
| JP (1) | JP6453781B2 (enExample) |
| CN (2) | CN105229171A (enExample) |
| CA (1) | CA2899712C (enExample) |
| ES (1) | ES2691306T3 (enExample) |
| WO (1) | WO2014140061A2 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201206486D0 (en) * | 2012-04-12 | 2012-05-30 | Sequessome Technology Holdings Ltd | Vesicular formulations and uses thereof |
| WO2018094569A1 (zh) * | 2016-11-22 | 2018-05-31 | 深圳华大基因研究院 | 多肽及其应用 |
| CN109913481B (zh) * | 2019-04-24 | 2020-04-03 | 无锡市第五人民医院 | PIK3CA基因g.179224821G＞A突变及其在乳腺癌辅助诊断中的应用 |
| KR102813811B1 (ko) * | 2020-03-27 | 2025-05-30 | 주식회사 젠큐릭스 | Pik3ca 돌연변이 검출용 조성물 및 이를 포함하는 키트 |
| CN111363827A (zh) * | 2020-04-30 | 2020-07-03 | 北京和合医学诊断技术股份有限公司 | 用于检测pik3ca基因突变的引物组及其应用方法 |
| CN114410790B (zh) * | 2022-01-27 | 2024-04-12 | 湖南大学 | 一种用于检测ctDNA的生物传感检测系统及其检测方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2663248T3 (es) * | 2004-03-02 | 2018-04-11 | The Johns Hopkins University | Mutaciones del gen de PIK3CA en cánceres humanos |
| GB2453173A (en) * | 2007-09-28 | 2009-04-01 | Dxs Ltd | Polynucleotide primers |
| JP5624044B2 (ja) * | 2008-10-20 | 2014-11-12 | エフ．ホフマン−ラ ロシュアーゲーＦ．Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 改善されたアレル−特異的増幅 |
| US20100286143A1 (en) * | 2009-04-24 | 2010-11-11 | Dora Dias-Santagata | Methods and materials for genetic analysis of tumors |
| US9238832B2 (en) * | 2009-12-11 | 2016-01-19 | Roche Molecular Systems, Inc. | Allele-specific amplification of nucleic acids |
| EP3246332B1 (en) * | 2010-01-12 | 2019-07-10 | Siemens Healthcare Diagnostics Inc. | Oligonucleotides and methods for detecting pik3ca mutations |
| CN102234685B (zh) * | 2010-04-23 | 2014-08-27 | 益善生物技术股份有限公司 | 一种pik3ca基因突变检测液相芯片 |
| KR101825121B1 (ko) * | 2010-08-13 | 2018-02-06 | 주식회사 파나진 | Ｐｎａ 기반의 실시간 ｐｃｒ 클램핑을 이용한 ｐｉｋ3ｃａ 돌연변이 검출 방법 및 키트 |
| JP6050820B2 (ja) * | 2011-09-23 | 2016-12-21 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 改良された対立遺伝子特異的ｐｃｒのためのｇ−クランプの使用 |
-
2014
- 2014-03-12 WO PCT/EP2014/054766 patent/WO2014140061A2/en not_active Ceased
- 2014-03-12 EP EP14709926.1A patent/EP2971075B1/en active Active
- 2014-03-12 CN CN201480013282.7A patent/CN105229171A/zh active Pending
- 2014-03-12 ES ES14709926.1T patent/ES2691306T3/es active Active
- 2014-03-12 CA CA2899712A patent/CA2899712C/en active Active
- 2014-03-12 JP JP2015562104A patent/JP6453781B2/ja active Active
- 2014-03-12 CN CN201810088883.4A patent/CN108130373A/zh active Pending
- 2014-03-12 US US14/205,751 patent/US20140272961A1/en not_active Abandoned
-
2016
- 2016-02-05 US US15/017,179 patent/US20160160297A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2899712A1 (en) | 2014-09-18 |
| JP2016510982A (ja) | 2016-04-14 |
| WO2014140061A3 (en) | 2014-10-30 |
| US20160160297A1 (en) | 2016-06-09 |
| EP2971075A2 (en) | 2016-01-20 |
| US20140272961A1 (en) | 2014-09-18 |
| EP2971075B1 (en) | 2018-08-15 |
| WO2014140061A2 (en) | 2014-09-18 |
| JP6453781B2 (ja) | 2019-01-16 |
| ES2691306T3 (es) | 2018-11-26 |
| CN105229171A (zh) | 2016-01-06 |
| CN108130373A (zh) | 2018-06-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kawano et al. | PIK3CA mutation status in Japanese lung cancer patients | |
| CN106715723B (zh) | 测定样品中pik3ca突变状态的方法 | |
| US20080286785A1 (en) | Method to predict or monitor the response of a patient to an erbb receptor drug | |
| CA2899712C (en) | Methods and compositions for detecting mutations in the human pi3kca (pik3ca) gene | |
| CN105593378B (zh) | 用于在人ezh2基因中检测突变的方法和组合物 | |
| US20120164641A1 (en) | Methods and Compositions for Detecting Mutation in the Human Epidermal Growth Factor Receptor Gene | |
| JP2013081450A (ja) | 多型検出用プローブ、多型検出方法、薬効判定方法及び多型検出用試薬キット | |
| CN106536758A (zh) | 利用夹紧探针及检测探针的多靶核酸检测方法的应用 | |
| JP2017169580A (ja) | 上皮増殖因子受容体キナーゼ・ドメイン内の新規な複合突然変異 | |
| JP6153758B2 (ja) | 多型検出用プローブ、多型検出方法、薬効判定方法及び多型検出用キット | |
| JP2016500253A (ja) | 上皮成長因子受容体キナーゼドメインにおける新規変異 | |
| JP2014076044A (ja) | 変異検出用プローブ、変異検出方法、薬効判定方法及び変異検出用キット |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20150729 |